Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Allarity Therapeutics Inc ALLR
$1.21
▼ -1.63%
($-0.02)
Open
$1.21
Prev Close
$1.23
Day Range
$1.19 – $1.24
52W Range
$0.77 – $2.35
Market Cap
$19.25M
Beta
0.54
EPS (TTM)
$-0.72
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-12-21 |
| Shares Out. | 15,910,000 |
| Website | allarity.com/ ↗ |
| Phone | 13026587581 |
| Employees | 8 |
| Revenue | $25,000 |
| Gross Profit | $25,000 |
| Net Income | -$2.8M |
| Free Cash Flow | -$16.7M |
| Total Assets | $34.9M |
| Total Liabilities | $28.0M |
| Equity | $6.9M |
About Allarity Therapeutics Inc
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Allarity Therapeutics Inc is a publicly traded company under the ticker symbol ALLR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)